New Device for Peripheral Nerve Stim Cuts Chronic Low Back Pain

This article originally appeared here.
Share this content:
New Device for Peripheral Nerve Stim Cuts Chronic Low Back Pain
New Device for Peripheral Nerve Stim Cuts Chronic Low Back Pain

MONDAY, March 20, 2017 (HealthDay News) -- A novel method of short-term percutaneous peripheral nerve stimulation (PNS) is useful for producing pain relief and reducing medication use among patients with chronic low back pain (LBP), according to a case report published online March 14 in Pain Practice.

Leonardo Kapural, M.D., Ph.D., from the Center for Clinical Research and Carolina's Pain Institute in Winston Salem, N.C., and colleagues describe the use of PNS in two subjects with chronic LBP. Stimulation was discontinued at the end of the one-month therapy and the leads were withdrawn.

The authors note that PNS produced clinically significant improvements in pain and functional outcomes (62 percent average reduction in Brief Pain Inventory Question #5, average pain; 73 percent reduction in disability, Oswestry Disability Index; 83 percent reduction in pain interference, Brief Pain Inventory). Non-opioid analgesic use was reduced by 83 percent on average, and the subject taking opioids ceased opioid use. Minor skin irritation caused by a topical dressing was the only adverse event. For at least four months after the start of therapy, clinically significant improvements were sustained (79 percent average reduction in pain; both reported minimal disability; and 100 and 74 percent reductions in opioids and non-opioids, respectively).

"This therapy has the potential to shift the paradigm in the management of chronic pain, offering a minimally invasive treatment with the potential to bring the benefits of an effective neuromodulation therapy to patients earlier in the treatment continuum," the authors write.

Several authors disclosed financial ties to SPR Therapeutics, which funded the study. Several authors are listed as inventors on issued or pending patents.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »